ID 109610
Title Transcription
セイジン Tサイボウ ハッケツビョウ ノ チリョウ
Title Alternative
How to treat Adult T-cell leukemia
Author
Takemoto, Shigeki Clinical Laboratory Department, National Hospital Organization Kumamoto Medical Center|Department of International Medical Cooperation, Graduate School of Medical Sciences, Kumamoto University
Keywords
ATL
HTLV‐1
allogeneic stem cell transplantation
CCR4
Content Type
Journal Article
Description
Since Takatsuki’s group noticed a new disease, adult T-cell leukemia (ATL), caused by retroviral infection, many researchers tried to figure out how to prevent the transmission and how to treat the neoplasm of mature T lymphocyte for 35 years. Blood borne infection was controlled and stopped after the screening of HTLV‐1 antibody started in 1986. However, once HTLV‐1 carriers develop to aggressive type of ATL including acute type and lymphoma-type, the median survival time is about one year and the patients relapse and die even during chemotherapy. It has been hard time for patients and families more than 25 years. Then, over the last 10 years, nation-wide studies resulted in the progression of treatment strategy for improvement of ATL patients’ survival. One is allogeneic stem cell transplantation undergone in patients available for and the other is a novel monoclonal antibody against chemokine receptor CCR4 on the surface of ATL cells. The new era of ATL treatment has come. Furthermore, novel predictive marker of ATL development and biomarker of ATL treatment are investigated to release patients from this incurable disease.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
69
Issue
1-2
Start Page
29
End Page
32
Sort Key
29
Published Date
2013-04-25
FullText File
language
jpn
TextVersion
Publisher